| Ytd | 0.22% | |
| 1y | 725.74% |
| Open | 221.32 | Prev Close | 221.32 | Low | 221.25 | High | 221.41 | Mkt Cap | 5.61B |
| Vol | 0.00 | Avg Vol | 1.37M | EPS | -11.20 | P/E | -19.77 | Forward P/E | 5.75 |
| Beta | 1.52 | Short Ratio | 1.34 | Inst. Own | 103.89% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-06 | 50-d Avg | 187.66 | 200-d Avg | 84.67 | 1yr Est | 221.50 |
CDTX News
Cidara Therapeutics, Inc. (NASDAQ: CDTX - Get Free Report) shares crossed above its 50-day moving av
Pharmaceuticals giant, Merck and Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug
ANB Bank bought a new position in shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) during the unde
Cidara Therapeutics, Inc. (NASDAQ: CDTX - Get Free Report) has been assigned a consensus recommendat
HighVista Strategies initiated a position in Cidara Therapeutics, buying 70,904 shares valued at $6.
Shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX - Get Free Report) have received a consensus recom
The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two
Geode Capital Management LLC grew its position in shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX)
Shareholders should contact the firm immediately as there may be limited time to enforce your rights
NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) -- We wish you a Happy Thanksgiving and Class Action Attorn
Merck's agreement to acquire Cidara Therapeutics for about $9.2 billion gives hVIVO PLC (AIM:HVO) a
hVIVO PLC (AIM:HVO) has praised its long-running partner Cidara Therapeutics after the American biot
Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysi
NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & A
Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way
The pharmaceutical giant's post-Keytruda plans continue to take shape.
Merck has announced plans to acquire Cidara Therapeutics for $9.2 billion, or $221.50 per share. Rep
In this week's edition of InnovationRx, we look at the biotech deal frenzy, Recursion's incoming CEO
In one of the most decisive strategic moves in the biotech sector this year, pharmaceutical titan Me
One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soar
Gainers
Gainers Biodexa Pharmaceuticals (NASDAQ: BDRX) shares rose 76% to $0.8276 in pre-market trading a
Monday's session saw 84 companies set new 52-week lows.
Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018
Stocks Which Set New 52-Week Low Yesterday, October 23rd